Developer docs
API playgroundTry for free, no card

Search company profiles

Effector Therapeutics

Full company profile

uuid0002188

Namestring
Effector Therapeutics
Legal namestring
eFFECTOR Therapeutics, Inc.
Websiteurl
effector.com
Company typeenum
Public
Founded yearint
2012
Short descriptiontext

eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company that developed small-molecule cancer therapeutics targeting eIF4E-mediated translation, with lead candidate tomivosertib; the company wound down operations in 2024 after a midstage trial failure.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer therapeutics, small molecule drugs, eIF4E inhibitors, translation control oncology, clinical-stage biopharmaceuticals
Industry4 codes
PRIMARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Oncology Biopharmaceuticals
No data
Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

eFFECTOR Therapeutics developed novel small molecule drugs targeting translation control in cancer, with its lead candidate tomivosertib designed as a selective MNK1/2 inhibitor to disrupt eIF4E-mediated tumor growth and survival pathways. The company partnered with Pfizer to advance inhibitor development and was working to address resistance mechanisms in cancer treatment.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Tomivosertib
CategoryCore product
Description

Lead product candidate; a selective MNK1/2 inhibitor targeting eIF4E-mediated tumor growth and survival pathways, investigated for cancer treatment in clinical-stage development.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Pfizer for developing inhibitors. The partnership focused on leveraging Pfizer's expertise alongside eFFECTOR's eIF4E translation control platform for cancer treatment development.

Peers10 records
TypeDirect peer
Description

Clinical-stage precision oncology company developing small-molecule therapies against oncogenic mutations. Highly comparable as a public, micro-cap clinical-stage oncology biotech with platform-based small-molecule discovery.

TypeDirect peer
Description

Clinical-stage precision oncology company using a motion-based drug design platform to develop small-molecule inhibitors against oncogenic targets. Comparable as a clinical-stage small-molecule oncology company pursuing differentiated mechanisms.

TypeDirect peer
Description

Clinical-stage precision oncology company focused on RAS/MAPK pathway small-molecule inhibitors. Comparable as a clinical-stage, public oncology biotech with single-mechanism focus and binary readouts.

TypeDirect peer
Description

Clinical-stage oncology company developing small-molecule drugs targeting synthetic lethal vulnerabilities in cancer. Comparable as a public clinical-stage oncology biotech leveraging a differentiated mechanistic platform.

TypeBroad incumbent
Description

Established clinical and commercial-stage precision oncology company developing kinase inhibitors. Comparable as a broader kinase/translation-targeting oncology player with operational scale beyond eFFECTOR's niche.

TypeEmerging player
Description

Clinical-stage biotech developing targeted protein degradation (TLR/IRAK, etc.) small molecules in oncology and immunology. Comparable as a public clinical-stage small-molecule oncology biotech with a novel mechanism platform.

TypeEmerging player
Description

Clinical-stage AI-driven drug discovery company with an oncology pipeline. Comparable as a publicly listed clinical-stage biotech pursuing novel mechanism discovery, though differentiated by its AI-discovery approach.

TypeBroad incumbent
Description

Precision oncology company developing targeted small-molecule inhibitors (acquired by Bristol Myers Squibb in 2024). Comparable as a clinical-stage precision oncology small-molecule player with a similarly concentrated pipeline profile.

TypeBroad incumbent
Description

Clinical-stage epigenetics-based oncology company (acquired by MorphoSys in 2021). Comparable as a public clinical-stage oncology company with a single platform mechanism and binary clinical readouts.

TypeEmerging player
Description

Private oncology drug discovery company pursuing precision oncology programs. Comparable as a small clinical/preclinical-stage oncology company with platform-based small-molecule discovery in a similar stage profile.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Effector Therapeutics

Oncology Biopharmaceuticalseffector.com

eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company that developed small-molecule cancer therapeutics targeting eIF4E-mediated translation, with lead candidate tomivosertib; the company wound down operations in 2024 after a midstage trial failure.

Effector Therapeutics firmographics

Firmographics
Name
Effector Therapeutics
Legal name
eFFECTOR Therapeutics, Inc.
Website
https://effector.com
Company type
Public
Founded year
2012
Operating status
Closed
Headcount range
11–50 employees
Short description
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company that developed small-molecule cancer therapeutics targeting eIF4E-mediated translation, with lead candidate tomivosertib; the company wound down operations in 2024 after a midstage trial failure.
Ownership category
akta.pro rank

Effector Therapeutics industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Cancer therapeutics
  • Small molecule drugs
  • EIF4E inhibitors
  • Translation control oncology
  • Clinical-stage biopharmaceuticals

Where Effector Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Effector Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Effector Therapeutics product offering

Product offering

Core offering

eFFECTOR Therapeutics developed novel small molecule drugs targeting translation control in cancer, with its lead candidate tomivosertib designed as a selective MNK1/2 inhibitor to disrupt eIF4E-mediated tumor growth and survival pathways. The company partnered with Pfizer to advance inhibitor development and was working to address resistance mechanisms in cancer treatment.

Differentiator

Problem solved

Functional benefit

Products and services

  • Tomivosertib Lead product candidate; a selective MNK1/2 inhibitor targeting eIF4E-mediated tumor growth and survival pathways, investigated for cancer treatment in clinical-stage development.

Companies that use Effector Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Effector Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Effector Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • PfizercoreStrategic or Co-development PartnerCollaboration with Pfizer for developing inhibitors. The partnership focused on leveraging Pfizer's expertise alongside eFFECTOR's eIF4E translation control platform for cancer treatment development.

Scale indicators4 records

Effector Therapeutics competitors and assessment

Company assessment

Direct peers

  • Black Diamond Therapeutics: Clinical-stage precision oncology company developing small-molecule therapies against oncogenic mutations. Highly comparable as a public, micro-cap clinical-stage oncology biotech with platform-based small-molecule discovery.
  • Relay Therapeutics: Clinical-stage precision oncology company using a motion-based drug design platform to develop small-molecule inhibitors against oncogenic targets. Comparable as a clinical-stage small-molecule oncology company pursuing differentiated mechanisms.
  • Erasca: Clinical-stage precision oncology company focused on RAS/MAPK pathway small-molecule inhibitors. Comparable as a clinical-stage, public oncology biotech with single-mechanism focus and binary readouts.
  • Tango Therapeutics: Clinical-stage oncology company developing small-molecule drugs targeting synthetic lethal vulnerabilities in cancer. Comparable as a public clinical-stage oncology biotech leveraging a differentiated mechanistic platform.

Broad incumbents

  • Blueprint Medicines: Established clinical and commercial-stage precision oncology company developing kinase inhibitors. Comparable as a broader kinase/translation-targeting oncology player with operational scale beyond eFFECTOR's niche.
  • Mirati Therapeutics: Precision oncology company developing targeted small-molecule inhibitors (acquired by Bristol Myers Squibb in 2024). Comparable as a clinical-stage precision oncology small-molecule player with a similarly concentrated pipeline profile.
  • Constellation Pharmaceuticals: Clinical-stage epigenetics-based oncology company (acquired by MorphoSys in 2021). Comparable as a public clinical-stage oncology company with a single platform mechanism and binary clinical readouts.

Emerging players

  • Kymera Therapeutics: Clinical-stage biotech developing targeted protein degradation (TLR/IRAK, etc.) small molecules in oncology and immunology. Comparable as a public clinical-stage small-molecule oncology biotech with a novel mechanism platform.
  • Recursion Pharmaceuticals: Clinical-stage AI-driven drug discovery company with an oncology pipeline. Comparable as a publicly listed clinical-stage biotech pursuing novel mechanism discovery, though differentiated by its AI-discovery approach.
  • Pimera (private): Private oncology drug discovery company pursuing precision oncology programs. Comparable as a small clinical/preclinical-stage oncology company with platform-based small-molecule discovery in a similar stage profile.

Market position

Customer concentration

Effector Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Effector Therapeutics leadership team

Management profile

Number of profiles

Effector Therapeutics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Effector Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Effector Therapeutics

What does Effector Therapeutics do?

eFFECTOR Therapeutics developed novel small molecule drugs targeting translation control in cancer, with its lead candidate tomivosertib designed as a selective MNK1/2 inhibitor to disrupt eIF4E-mediated tumor growth and survival pathways. The company partnered with Pfizer to advance inhibitor development and was working to address resistance mechanisms in cancer treatment.

Is Effector Therapeutics a public or private company?

Effector Therapeutics is a public company. It is classified as public and is currently closed.

When was Effector Therapeutics founded?

Effector Therapeutics was founded in 2012. It employs 11 to 50 people.

Where is Effector Therapeutics based?

Effector Therapeutics is headquartered in San Diego, United States, in the North America region.

Who are Effector Therapeutics's main competitors?

Direct peers on record are Black Diamond Therapeutics, Relay Therapeutics, Erasca and Tango Therapeutics. Broad incumbents are Blueprint Medicines, Mirati Therapeutics and Constellation Pharmaceuticals. Emerging players are Kymera Therapeutics, Recursion Pharmaceuticals and Pimera (private).

Does Effector Therapeutics have an API?

No public API is recorded for Effector Therapeutics.

What industry is Effector Therapeutics in?

Effector Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIALAB, Lead Optimization & Preclinical Candidate Selection, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldeFFECTOR Therapeutics (NASDAQ:EFTR) versus Spruce Biosciences (NASDAQ:SPRB) Critical SurveyThis article provides a comparative financial analysis of two small-cap biopharmaceutical companies: eFFECTOR Therapeutics and Spruce Biosciences, evaluating metrics including valuation, earnings, analyst recommendations, volatility, and institutional ownership. Spruce Biosciences is noted to have stronger analyst consensus ratings and significantly higher institutional ownership (91.7%) compared to eFFECTOR Therapeutics (57.7%), while eFFECTOR shows better earnings metrics with lower net losses per share. Neither company generates meaningful revenue, with both posting substantial net losses (eFFECTOR: -$35.81M; Spruce: -$38.97M).openPR.comBest Statistical RNA Targeted Therapeutics Market Growth Set to Surge Significantly during 2025 to 2032 | Abivax, AC Immune, Arrakis Therapeutics, eFFECTOR TherapeuticsThe RNA targeted therapeutics market is projected to grow from USD 1.34 billion in 2024 to USD 11.2 billion by 2031, a CAGR of 35.2%. Key players include Abivax, AC Immune, Arrakis Therapeutics, and eFFECTOR Therapeutics, with segmentation by target molecule and approach.BenzingaeFFECTOR Therapeutics (OTC:EFTR) Stock, Short Interest ReportShort interest in eFFECTOR Therapeutics fell from 686.98K to 6.58K, representing 0.14% of publicly available shares. Based on average daily volume of 930.59K shares, it would take one day to cover the short positions without pushing the stock sharply higher.stockhouseKaskela Law LLC Announces Investigation of eFFECTOR Therapeutics, Inc. (EFTR) and Encourages Former eFFECTOR Employees to Contact the FirmKaskela Law LLC announced an investigation of eFFECTOR Therapeutics on behalf of former employees. The investigation examines whether the 2021 SPAC acquisition's share conversion was fair and compliant with securities laws, or if former shareholders were financially harmed. Former employees are encouraged to contact the firm for information.Business InsiderKaskela Law LLC Announces Investigation of eFFECTOR Therapeutics, Inc. (EFTR) and Encourages Former eFFECTOR Employees to Contact the FirmKaskela Law LLC announced an investigation of eFFECTOR Therapeutics on behalf of former employees, seeking to determine if the share conversion from Legacy eFFECTOR to the SPAC was fair and compliant with securities laws. The firm encourages former employees to contact it for information on their legal rights and options.TradingVieweFFECTOR Therapeutics slumps on plans to stop development of lung cancer therapyeFFECTOR Therapeutics shares fell 78.6% to $3.53 after the company announced it will discontinue development of its experimental lung cancer therapy tomivosertib. The drug showed modest activity in a mid-stage study, but the company sees no obvious path forward. The stock is down about 69.8% year-to-date.YahooDoes eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?eFFECTOR Therapeutics shares closed at $11.70, with analysts' mean price target of $107 implying an 814.5% upside. The consensus includes targets from $21 to $175, and earnings estimates have been revised higher, supporting near-term upside potential.GlobeNewswireeFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RuleseFFECTOR Therapeutics closed a registered direct offering of 1,488,834 shares and short-term warrants at $10.075 per share, generating approximately $15 million in gross proceeds. The company will use the net proceeds for general corporate and working capital, including research and development. The short-term warrants are exercisable immediately and expire three and a half years from issuance.YahooeFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RuleseFFECTOR Therapeutics closed a registered direct offering of 1,488,834 shares and short-term warrants at $10.075 per share, generating approximately $15 million in gross proceeds. The company will use the net proceeds for general corporate and working capital, including research and development. The short-term warrants are exercisable immediately and expire three and one-half years from issuance.GlobeNewswireeFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RuleseFFECTOR Therapeutics announced a $15 million registered direct offering of common stock and warrants, priced at $10.075 per share under Nasdaq rules. H.C. Wainwright & Co. is acting as the exclusive placement agent for this transaction with the single healthcare-focused institutional investor. The company intends to use the net proceeds for general corporate purposes, including funding its research and development efforts.